| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma
|
Kobbe, G.
|
|
|
21 |
9 |
p. 1898-1904
|
artikel
|
| 2 |
Adjuvant chemotherapy in rectal cancer—an issue or a nonissue?
|
Glimelius, B.
|
|
|
21 |
9 |
p. 1739-1741
|
artikel
|
| 3 |
All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer
|
Coumans, F.A.W.
|
|
|
21 |
9 |
p. 1851-1857
|
artikel
|
| 4 |
A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease
|
Zatloukal, P.
|
|
|
21 |
9 |
p. 1810-1816
|
artikel
|
| 5 |
‘A no means no’—measuring depression using a single-item question versus Hospital Anxiety and Depression Scale (HADS-D)
|
Skoogh, J.
|
|
|
21 |
9 |
p. 1905-1909
|
artikel
|
| 6 |
A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy
|
Kanagavel, D.
|
|
|
21 |
9 |
p. 1779-1785
|
artikel
|
| 7 |
Cancer profile in Eastern Libya: incidence and mortality in the year 2004
|
El Mistiri, M.
|
|
|
21 |
9 |
p. 1924-1926
|
artikel
|
| 8 |
Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer
|
Hardy, D.
|
|
|
21 |
9 |
p. 1825-1833
|
artikel
|
| 9 |
Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence
|
Mozley, P.D.
|
|
|
21 |
9 |
p. 1751-1755
|
artikel
|
| 10 |
Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study
|
Zaanan, A.
|
|
|
21 |
9 |
p. 1786-1793
|
artikel
|
| 11 |
Clinical outcome of leiomyosarcomas of vascular origin: comparison with leiomyosarcomas of other origin
|
Italiano, A.
|
|
|
21 |
9 |
p. 1915-1921
|
artikel
|
| 12 |
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy
|
Bidard, F.-C.
|
|
|
21 |
9 |
p. 1765-1771
|
artikel
|
| 13 |
Communication about high-cost drugs in oncology—the patient view
|
Kaser, E.
|
|
|
21 |
9 |
p. 1910-1914
|
artikel
|
| 14 |
Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials
|
Bujko, K.
|
|
|
21 |
9 |
p. 1743-1750
|
artikel
|
| 15 |
Editorial board
|
|
|
|
21 |
9 |
p. ii-iii
|
artikel
|
| 16 |
Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation
|
Calvo-Villas, J.M.
|
|
|
21 |
9 |
p. 1891-1897
|
artikel
|
| 17 |
Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies
|
Reddy, N.
|
|
|
21 |
9 |
p. 1756-1764
|
artikel
|
| 18 |
ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial
|
Vilmar, A.C.
|
|
|
21 |
9 |
p. 1817-1824
|
artikel
|
| 19 |
FDG–PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study
|
Lopci, E.
|
|
|
21 |
9 |
p. 1877-1883
|
artikel
|
| 20 |
From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer
|
Aletti, G.D.
|
|
|
21 |
9 |
p. 1772-1778
|
artikel
|
| 21 |
Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE)
|
Garcia-Carbonero, R.
|
|
|
21 |
9 |
p. 1794-1803
|
artikel
|
| 22 |
In this issue
|
|
|
|
21 |
9 |
p. 1737
|
artikel
|
| 23 |
Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study
|
Tandstad, T.
|
|
|
21 |
9 |
p. 1858-1863
|
artikel
|
| 24 |
Misrepresentation
|
Ernst, E.
|
|
|
21 |
9 |
p. 1927
|
artikel
|
| 25 |
Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: a meta-analysis of randomized controlled trials
|
Tunio, M.A.
|
|
|
21 |
9 |
p. 1839-1845
|
artikel
|
| 26 |
Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor
|
Ehrlich, Y.
|
|
|
21 |
9 |
p. 1846-1850
|
artikel
|
| 27 |
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
|
Reck, M.
|
|
|
21 |
9 |
p. 1804-1809
|
artikel
|
| 28 |
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
|
Morschhauser, F.
|
|
|
21 |
9 |
p. 1870-1876
|
artikel
|
| 29 |
Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases
|
Ruggeri, E.M.
|
|
|
21 |
9 |
p. 1926-1927
|
artikel
|
| 30 |
Sunitinib-induced reduction in skin microvascular density is a reversible phenomenon
|
de Boer, M.P.
|
|
|
21 |
9 |
p. 1923-1924
|
artikel
|
| 31 |
Table of Contents
|
|
|
|
21 |
9 |
p. iv-v
|
artikel
|
| 32 |
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network
|
Malouf, G.G.
|
|
|
21 |
9 |
p. 1834-1838
|
artikel
|
| 33 |
The expression of p38, ERK1 and Bax proteins has increased during the treatment of newly diagnosed acute promyelocytic leukemia with arsenic trioxide
|
Mandegary, A.
|
|
|
21 |
9 |
p. 1884-1890
|
artikel
|
| 34 |
Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer
|
Rajpar, S.
|
|
|
21 |
9 |
p. 1864-1869
|
artikel
|
Tijdschrift beschrijving